Drug repurposing: Clinical practices and regulatory pathways
Perspectives in Clinical Research · 2025-04 · 16 (2) · 61-68
DOI: 10.4103/picr.picr_70_24 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Perspectives in Clinical Research, online erschienen am 10.09.2024. Verfasst von K Saranraj und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Rangaraya Medical College, Kakinada, Andhra Pradesh, India. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Drug repurposing, also known as drug repositioning or reprofiling, involves identifying new therapeutic uses for existing drugs beyond their original indications. Historical examples include sildenafil citrate transitioning to an erectile dysfunction treatment and thalidomide shifting from a sedative to an immunomodulatory agent. Advocates tout its potential to address unmet medical needs by expediting development, reducing costs, and using drugs with established safety profiles. However, concerns exist regarding specificity for new indications, safety, and regulatory exploitation. Ethical considerations include equitable access, informed consent when using drugs off-label, and transparency. Recent advancements include artificial intelligence (AI) applications, network pharmacology, and omics technologies. Clinical trials explore repurposed drugs’ efficacy, with regulatory agencies facilitating approval. Challenges include intellectual property protection, drug target specificity, trial design complexities, and funding limitations. Ethical challenges encompass patient autonomy, potential conflicts of interest due to financial incentives for industries, and resource allocation. Future directions involve precision medicine, AI, and global collaboration. In conclusion, drug repurposing offers a promising pathway for therapeutic innovation but requires careful consideration of its complexities and ethical implications to maximize benefits and minimize risks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Rangaraya Medical College, Kakinada, Andhra Pradesh, India.
Zitieren
APA
Saranraj, K., & Kiran, P. U. (2025). Drug repurposing: Clinical practices and regulatory pathways. Perspectives in Clinical Research, 16(2), 61-68. https://doi.org/10.4103/picr.picr_70_24
Vancouver
Saranraj K, Kiran PU. Drug repurposing: Clinical practices and regulatory pathways. Perspectives in Clinical Research. 2025;16(2):61-68. doi:10.4103/picr.picr_70_24
BibTeX
@article{Saranraj2025,
author = {Saranraj, K and Kiran, P Usha},
title = {Drug repurposing: Clinical practices and regulatory pathways},
journal = {Perspectives in Clinical Research},
year = {2025},
volume = {16},
number = {2},
pages = {61--68},
doi = {10.4103/picr.picr_70_24}
}
EUVIMED